Medical field
POPULARITY
Categories
98 episodes with Gene therapy
54 episodes with Gene therapy
43 episodes with Gene therapy
29 episodes with Gene therapy
20 episodes with Gene therapy
19 episodes with Gene therapy
21 episodes with Gene therapy
19 episodes with Gene therapy
12 episodes with Gene therapy
10 episodes with Gene therapy
15 episodes with Gene therapy
19 episodes with Gene therapy
8 episodes with Gene therapy
16 episodes with Gene therapy
14 episodes with Gene therapy
6 episodes with Gene therapy
13 episodes with Gene therapy
19 episodes with Gene therapy
14 episodes with Gene therapy
12 episodes with Gene therapy
26 episodes with Gene therapy
19 episodes with Gene therapy
14 episodes with Gene therapy
12 episodes with Gene therapy
4 episodes with Gene therapy
9 episodes with Gene therapy
7 episodes with Gene therapy
7 episodes with Gene therapy
10 episodes with Gene therapy
6 episodes with Gene therapy
14 episodes with Gene therapy
10 episodes with Gene therapy
5 episodes with Gene therapy
8 episodes with Gene therapy
7 episodes with Gene therapy
7 episodes with Gene therapy
11 episodes with Gene therapy
8 episodes with Gene therapy
21 episodes with Gene therapy
7 episodes with Gene therapy
7 episodes with Gene therapy
4 episodes with Gene therapy
5 episodes with Gene therapy
5 episodes with Gene therapy
6 episodes with Gene therapy
6 episodes with Gene therapy
6 episodes with Gene therapy
6 episodes with Gene therapy
6 episodes with Gene therapy
5 episodes with Gene therapy
7 episodes with Gene therapy
2 episodes with Gene therapy
4 episodes with Gene therapy
5 episodes with Gene therapy
Dr. William Li: Eat to Beat Disease, Extend Longevity, and Hack Your Vascular Health Your body already has a built-in cancer defense system, and the foods you eat can rival prescription drugs at activating it. In this episode, you'll discover what 720,000 living centenarians reveal about longevity, why microplastics are reaching your brain through your nose, and how your blood vessels hold the real key to biological aging. -Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey sits down with Dr. William Li, an internationally renowned physician, scientist, and two-time New York Times bestselling author of "Eat to Beat Disease" and "Eat to Beat Your Diet." As President and Medical Director of the Angiogenesis Foundation, Dr. Li's groundbreaking research has led to the development of more than 40 new medical treatments impacting care for over 70 diseases including diabetes, heart disease, blindness, and obesity. His TED Talk, "Can We Eat to Starve Cancer?", has surpassed 11 million views, making him one of the most trusted voices at the intersection of functional medicine and food as medicine science. Together they dig into the biology of SuperAgers, the vascular markers that predict how long you'll live, and why flow-mediated dilation may be the most underrated biohacking measurement tool available today. Dave shares what happened after four separate gene therapies, including klotho and VEGF, and Dr. Li explains why your metabolism, mitochondria, and gut microbiome show up in the data on every centenarian ever studied. They also get into the microplastic crisis, the cribriform plate pathway that delivers airborne particles directly to your brain, and why your tongue is the first place your body quietly stores fat. You'll Learn: What centenarian research reveals about immune function, gut health, and vascular resilience Why 50% of food extracts matched or outperformed cancer drugs in head-to-head angiogenesis testing How microplastics travel through your nose directly to your central nervous system What flow-mediated dilation and pulse wave velocity tell you about your true biological age Why your hind-third tongue fat is an overlooked early warning sign for sleep apnea and metabolism problems What Dave's four gene therapies (klotho, VEGF, follistatin) actually did to his body How the vagus nerve connects gut health to brain optimization, stress resilience, and longevity Why genetics now accounts for roughly half of longevity outcomes, and what that means for the future of gene therapy How to use biohacking tools to compound your health the same way you compound financial returns Thank you to our sponsors! - Beyond Wonderland Conference | Oct 13 - 14, 2026. Get your ticket now at wonderlandconference.com. - Amp | If you're ready to make fitness fit into your life, go to amp.ai to check it out - Caldera + Lab | A small habit with big results. Go to CalderaLab.com/DAVE and use code DAVE for 20% off your first order. - Calroy | Go to Calroy.com/DAVE for exclusive discounts on Arterosil HP, Vascanox HP and all Calroy products. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights inhealth, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: William Li, Dr. William Li, Eat to Beat Disease, angiogenesis, food as medicine, centenarians, SuperAgers, longevity, anti-aging, biohacking, vascular health, flow-mediated dilation, pulse wave velocity, microplastics, cribriform plate, gene therapy, klotho, VEGF, follistatin, mitochondria, metabolism, gut health, vagus nerve, sleep apnea, functional medicine, human performance, brain optimization, cancer prevention, inflammation, immune system Resources: • Learn More About Dr. Li's Work At: https://drwilliamli.com • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Trailer 02:33 – William's Background 06:21 – Food vs. Cancer Drugs 14:09 – Gene Therapy 23:50 – Centenarian Research 27:41 – Stress & the Vagus Nerve 37:31 – Vascular Health 42:34 – Microplastics 53:19 – Novel Biomarkers See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
A panel of clinical pharmacists meets to discuss the complex process of operationalizing cell and gene therapy at an academic medical center.
Send us Fan MailSometimes we hear about a vision for a trial that is so novel and exciting that it takes you back a bit.This is one such moment.Join us as we talk to the amazing Dr Faye Robertson from the Edinburgh cancer Centre about the ingenious ADePT trial.DUAL PAYLOAD GENE THERAPY.Led by Trogenix and the University of Edinburgh, it tests a breakthrough "Trojan horse" gene therapy designed to destroy cancer cells and stimulate the immune system.TGX-007 is a drug developed with Tregonix that:How it Works: It uses dual-payload technology to deliver two distinct therapeutic agents:HSV-tk: Converts an orally administered antiviral drug (valaciclovir) into a toxic agent that directly kills proliferating tumour cells.IL-12: Acts as an immune-stimulating cytokine that turns the tumour into an in-situ vaccine, training the body's immune system to attack the cancer and prevent recurrence.We have had many false dawns in GBM trials but we are very excited by the results so far with TGX-007.Part 1 of 2 and this is a trial story we want to follow through.Enjoy!!!
Friedreich's ataxia is a progressive, multisystem disease that robs people of coordination, independence, and often life itself. Until recently, there had been no approved therapies. In Friedreich's ataxia, a genetic mutation causes a deficiency in frataxin, a protein that plays an essential role within mitochondria and affects enzymes involved in energy production. Solid Biosciences is developing a gene therapy designed to restore frataxin where it is needed. Friedreich's Ataxia Research Alliance CEO Jennifer Farmer and Solid Biosciences chief medical officer Gabriel Brooks discuss the lived reality of Friedreich's ataxia, Solid Bioscience's next-generation gene therapy now in development to address the underlying cause of the disorder, and what genuine partnerships between patient organizations and industry look like when patient priorities drive trial design and development decisions.
Send us Fan MailBladder cancer treatment is entering a new era. From gene therapy and bladder preservation to AI-assisted diagnostics and the challenge of detecting “hidden” CIS, Dr. Ravi Chauhan, MD, FACS breaks down the technologies and clinical decisions reshaping urology in 2026.Dr. Ravi Chauhan, MD, FACS ( https://conradpearson.com/our-specialists/ravi-d-chauhan-m-d-facs/ ) is a board-certified urologist, fellowship-trained uro-oncology specialist, and one of the leading voices in advanced kidney and bladder cancer care in the Mid-South.Born and raised in Memphis, Tennessee, Dr. Chauhan graduated Cum Laude from Rhodes College with a degree in molecular biology before earning his M.D. and completing both his general surgery internship and urologic surgery residency at The University of Tennessee Health Science Center. He joined the Conrad Pearson Clinic in 2005 and has since become a recognized leader in the treatment of advanced bladder and kidney cancers, with numerous publications and presentations to his name.Dr. Chauhan's path into medicine was deeply personal. Inspired by watching his father practice medicine and witnessing the profound impact physicians can have on patients and families, he developed a philosophy centered on treating every patient with the same compassion, respect, and attention he would want for his own family.In addition to his expertise in surgical urology and uro-oncology, Dr. Chauhan has become increasingly focused on one of the biggest challenges in modern bladder cancer management: identifying and treating high-risk non–muscle invasive bladder cancer - or NMIBC, particularly carcinoma in situ - or CIS , which can often be difficult to detect in routine clinical practice.Today, we'll discuss the evolving diagnostic landscape for CIS, why missed or under-recognized disease can significantly impact treatment decisions, and the growing importance of collaboration between urologists and pathologists. We'll also explore how community urologists are navigating these rapidly evolving standards of care, the future of precision bladder cancer management, and what it means for patients facing this disease.We'll also discuss bladder-sparing approaches, including Adstiladrin® (nadofaragene firadenovec-vncg), an intravesical gene therapy for adults with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive NMIBC with CIS, with or without papillary ( https://www.adstiladrin.com/ ).ADSTILADRIN should not be used in patients with hypersensitivity to interferon alfa or its components, and individuals who are immunosuppressed or immune-deficient should not handle or receive the therapy. Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.The most common adverse reactions include urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in urine. Patients should consult their healthcare provider regarding all medications and report any side effects. Please see full Prescribing Information ( https://d2hu1op93domjx.cloudfront.net/wp-content/uploads/sites/12/2026/03/24101239/ADSTILADRIN-USPI-Mar.2026-CLEAN.pdf ) for additional details.#BladderCancer #Urology #CancerResearch #BladderCancerAwareness #NMIBC #CarcinomaInSitu #CIS #UroOncology #GeneTherapy #CancerTreatment #PrecisionMedicine #BCG #BladderPreservation #MedicalInnovation #Oncology #CancerCare #Immunotherapy #HealthcareInnovation #UrologistSupport the show
Today's episode is a very special one. We are joined by Anna and her mother, Chelle, to discuss what it is like to live with Leber congenital amaurosis (or LCA) and to understand the patient experience of receiving retinal gene therapy with Luxturna, the first FDA approved gene therapy in medicine. Subscribe to the podcast: https://MayoClinicOphthalmology.podbean.com Follow and reach out to us on X and IG: @mayocliniceye
Gene therapy is changing how clinicians care for patients with rare and genetic diseases, with more therapies moving from research into clinical use. In this episode, Dr. Nirali Shah is joined by Dr. Christy Duncan and Dr. Sung‑Yun Pai to talk through recent progress in the field and what it actually takes to deliver these treatments at the patient level.The discussion draws on their experience in transplant and genetic disease, covering both scientific advances and the operational challenges that come with implementing gene therapy — especially in complex and resource‑intensive settings. Tune in for a conversation that covers:Recent developments in gene therapy, including in vivo approaches and newly approved treatmentsBarriers to broader use, including access, equity, and long-term monitoringWhat centers need to consider when building a gene therapy program, from workflows to team coordinationWhere things may be heading, including more individualized therapies and efforts to expand availabilityListen to the episode below or on your favorite app. Subscribe to ASTCT Talks and share this episode with your colleagues to keep the conversation going.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest news shaping the industry, from breakthroughs in cancer therapies to advancements in AI-driven drug discovery. Starting with regulatory updates, the potential appointment of Richard Pazdur, M.D., as the new FDA Commissioner is causing quite a stir. Following Marty Makary's resignation, Pazdur has emerged as a prominent candidate due to his extensive background in oncology drug regulation. Known for his commitment to accelerating cancer therapy approvals, his potential leadership could maintain or even amplify the focus on expediting innovative treatments for cancer patients. In a significant regulatory achievement, Beone Medicines celebrated the FDA's approval of Beqalzi, marking it as the first BCL-2 inhibitor approved for mantle cell lymphoma. This approval challenges AbbVie's Venclexta and underscores a growing trend towards targeted cancer therapies that offer new treatment avenues for patients. The oncology space continues to be fiercely competitive, with companies striving to deliver more precise and effective cancer treatments. Turning to clinical trials, AstraZeneca's Imfinzi has shown promising results in a phase 3 trial focused on bladder cancer patients who are not eligible for cisplatin-based chemotherapy. These findings position Imfinzi as a strong competitor to Merck's Keytruda and reinforce AstraZeneca's strategic focus on expanding its oncology portfolio through novel combinations and indications. In the realm of genetic therapies, Regenxbio has achieved a milestone with its gene therapy for Duchenne muscular dystrophy. This therapy met its primary endpoint in pivotal trials, highlighting the potential of gene therapies to address rare diseases with limited treatment options. Such successes are likely to encourage further investment in gene editing technologies, which hold significant promise for tackling conditions once deemed untreatable. The FDA is also exploring frameworks to repurpose existing drugs for new uses by leveraging existing safety data. This could streamline drug development processes and offer cost-effective solutions for patients with complex conditions. However, this approach will need rigorous validation of efficacy in new indications to ensure patient safety and therapeutic effectiveness. Despite setbacks in its Alzheimer's research, Biogen remains steadfast in its efforts. While their tau-targeting candidate did not meet primary endpoints in a phase 2 trial, reductions in tau pathology and cognitive benefits were observed. This perseverance showcases Biogen's commitment to finding innovative approaches to tackle Alzheimer's disease despite ongoing challenges. On the operational front, Taiwan's Bora Group is acquiring Macrogenics' CDMO operations for up to $127.5 million. This move reflects a broader trend of consolidation within the CDMO space as companies aim to enhance their production capabilities and streamline operations. Quality control remains a critical concern as evidenced by Sun Pharma's recent recall of a chemotherapy batch due to glass particle contamination. Incidents like these underline the importance of stringent quality assurance measures throughout the manufacturing process to ensure patient safety. Moreover, Viz.ai has launched an AI-powered pulmonary care platform aimed at integrating acute and chronic care workflows. This development signals an increasing adoption of artificial intelligence in healthcare, promising improvements in diagnostics and patient management efficiency. AI continues to gain traction as Isomorphic Labs recently secured $2.1 billion in Series B funding aimed at enhancing AI-driven drug design models. Similarly, Charles River has introduced an AI-powered digital pathology platform poised to Support the show
In this episode of Genetics in Your World, GSA Early Career Scientists Multimedia Subcommittee member Luke Arnce interviews Caitlin Peaslee of the Center for Embryonic Cell and Gene Therapy at Oregon Health and Science University about her research. Read her paper titled, "Mapping whole-organism genetic comorbidities across model species using unified ontologies," published in the April 2026 issue of GENETICS: https://doi.org/10.1093/genetics/iyag038 This study developed a cross-species computational framework, CoMo DBM, to analyze 204 mouse genes that caused non-obstructive azoospermia and mapped their phenotype associations across human, zebrafish, fruit fly, and roundworm databases. Music: Loopster Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 License, http://creativecommons.org/licenses/by/3.0/#GeneEditing #cancer #GeneOntology Hosted on Acast. See acast.com/privacy for more information.
Saffie, a six-year-old girl from Stevenage who has the rare inherited eye condition Leber's Congenital Amaurosis (LCA), which prevents cells in the eye from making a specific protein needed for normal vision.After tests were carried out at Moorfields Eye Hospital in London, she was treated at Great Ormond Street Hospital (GOSH) and underwent Luxturna eye gene therapy treatment performed by Consultant Ophthalmologist Rob Henderson which has made a real difference to her vision and her life. RNIB Connect Radio's Toby Davey was joined by Saffie's Mother Lisa Samford and Consultant Ophthalmologist Rob Henderson to find out more about Leber's Congenital Amaurosis, how the condition affects people's vision, the eye gene therapy treatment and how the treatment has made a real difference to Saffie's life.You will find more about Leber's Congenital Amaurosis and the eye gene therapy treatment in the following news article on the Moorfields Eye Hospital website -https://www.moorfields.nhs.uk/about-us/news-and-blogs/news/moorfields-breakthrough-treatment-shows-promise-in-children (Image shows the RNIB Connect Radio logo. On a white background ‘RNIB' written in bold black capital letters and underlined with a bold pink line. Underneath the line: ‘Connect Radio' is written in black in a smaller font)
Gene therapy has been quietly pulling off miracles, and this week, it got its Oscars moment. Emma Varvaloucas, Executive Director of The Progress Network, breaks down how a husband-and-wife scientific team's decades-long quest has restored sight to over 100 blind Americans, and how a brand-new drug called Otarmeni just became the first-ever FDA-approved gene therapy for genetic deafness. The science is extraordinary. The price tags, less so.Plus: The United Kingdom passes a genuinely radical generational ban on smoking; the US Senate unanimously bans members and staffers from betting on prediction markets, after some were caught betting on their own races; and Meta inks a deal to beam solar power down from space.What Could Go Right? is produced by The Progress Network and Kaleidoscope.For transcripts, to join the newsletter, and for more information, visit: theprogressnetwork.orgSubscribe to our (FREE) Substack newsletter: https://theprogressnetwork.org/newsletter/Watch the podcast on YouTube: / theprogressnetworkFollow us on X, Instagram, Facebook, TikTok: @progressntwrkFollow Emma on Instagram: https://www.instagram.com/heyemmavarv/
2020 Llura Liggett Gund Award recipient honored for pioneering gene therapy that transformed vision research
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In a rapidly evolving industry landscape, artificial intelligence has emerged as a game-changer, transforming how major pharmaceutical companies approach drug development and diagnostics. Roche's strategic acquisition of PathAI for over $1 billion exemplifies this shift, highlighting the growing importance of AI-driven diagnostics in digital pathology. This move signals a broader trend where AI is no longer just a theoretical concept but a practical tool enhancing healthcare delivery. Alnylam's recent challenges with its web-based presentation of Amvuttra data underscore the need for accuracy in representing clinical data digitally—showing that while AI can offer innovative ways to present data, it also demands rigorous standards to ensure clarity and prevent misleading claims. On the regulatory front, the FDA's evolving stance on cell therapy Ebvallo, alongside its new one-day assessment pilot program, is shaping the industry's regulatory environment. The reconsideration of Ebvallo's earlier rejection due to single-arm trial data concerns illustrates the FDA's willingness to adapt its regulatory framework to accommodate innovative therapies. This adjustment could potentially pave the way for other gene therapies in development, including those by UniQure. Moreover, Sanofi's withdrawal of Tzield from the FDA's contentious Commissioner's National Priority Voucher program reflects ongoing debates about expedited review processes, underscoring the need for transparent and efficient pathways for bringing new therapies to patients swiftly. Additionally, the FDA's AI-guided inspection pilot aims to modernize compliance strategies and enhance pharmaceutical manufacturing oversight. In clinical trials, companies continue to face both triumphs and setbacks. Entrada Therapeutics experienced a significant decline in stock value following underwhelming Duchenne Muscular Dystrophy trial results, potentially reshaping competitive dynamics in favor of rivals like Novartis. Conversely, Angelini Pharma is making strategic moves with its $4.1 billion acquisition of Catalyst Pharmaceuticals, targeting market expansion in the U.S. through Firdapse, which is poised to make significant impacts in treating rare diseases. MingMed Biotechnology's promising phase 2 results for QA102 could signal new treatment paradigms for dry AMD—a condition with limited current interventions. Therapeutic innovation is also being driven by policy shifts that encourage research into psychedelic drugs for mental health treatment. Optimi Health's IPO indicates growing investor interest in this area, fueled by regulatory easing under recent executive orders aimed at facilitating psychedelic research. Strategic pipeline adjustments are evident as companies realign their focus based on emerging data insights. Ascendis Pharma's decision to halt its IL-2 oncology program marks a shift toward more promising avenues, while Beone Medicines' restructuring reflects a similar strategy by discontinuing several early-stage cancer programs. The industry's dynamism is further illustrated by Eli Lilly's substantial $4.5 billion investment in expanding its Indiana campus. This move not only enhances Lilly's capacity for genetic medicine and metabolic disease manufacturing but also underscores a broader industry commitment to precision medicine and biologics—fields anticipated to play pivotal roles in future healthcare solutions. Meanwhile, Bayer's acquisition of Perfuse Therapeutics seeks to bolster its ophthalmology portfolio, addressing significant unmet needs in eye disease treatments. Novo Nordisk's success with Wegovy highlights strong market demand for effective obesity treatments, demonstrating an industry-wide shift towards addressing lifestyle-related diseases. LegislSupport the show
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode dives into the ever-evolving landscape of the pharmaceutical and biotechnology industries, which are experiencing significant transformations driven by scientific advancements, strategic realignments, and regulatory changes. Sanofi is making a significant move by investing $294 million to expand its AI center of excellence in Toronto. This investment is part of a broader trend in the sector to optimize pharmaceutical operations and accelerate drug development through digital transformation. By enhancing its AI capabilities, Sanofi aims to streamline processes and reduce time-to-market for new drugs, positioning itself as a leader in this digital era. In clinical trials, Cytokinetics has reported a pivotal success with MyoKardia's drug Myqorzo in a Phase 3 trial aimed at treating non-obstructive hypertrophic cardiomyopathy. If approved, Myqorzo would be the first treatment available for this condition, highlighting ongoing efforts within the industry to address unmet medical needs with innovative therapies. However, not all ventures meet expectations. Pfizer's acquisition of Trillium Therapeutics for $2.3 billion did not materialize as hoped, leading to the discontinuation of its remaining clinical-stage candidates. This outcome underscores the risks inherent in pharmaceutical investments and the importance of thorough evaluation of potential therapeutic candidates. Similarly, Vertex Pharmaceuticals encountered challenges with its inhaled cystic fibrosis candidate developed with Moderna due to tolerability issues, highlighting patient safety's role in clinical trials. Strategic shifts are also taking place in workforce management. BioNTech plans to cut 1,860 jobs as it exits manufacturing sites in Germany and Singapore, reflecting broader industry trends toward operational optimization. Similarly, Novartis is closing its manufacturing site in Wehr, Germany, resulting in 220 job cuts as part of efforts to streamline operations. Regulatory developments continue to shape industry dynamics. Axsome Therapeutics received FDA approval for Auvelity as a treatment for agitation associated with Alzheimer's disease. This not only enhances Axsome's market potential but also underscores the critical role of regulatory agencies in facilitating access to treatments for complex conditions. Moreover, CAR-T therapies are expanding beyond oncology into autoimmune diseases. Kyverna Therapeutics is advancing toward a groundbreaking approval for CAR-T therapy in autoimmune disorders, marking an evolution in therapeutic applications. The recent developments underscore a dynamic phase characterized by technological innovation and strategic restructuring. AI technologies are revolutionizing drug discovery processes while successful clinical trials expand treatment options for previously unmet needs. Yet challenges remain with investment risks and organizational realignments reshaping operational strategies. Pfizer's discontinuation of its investment in Trillium Therapeutics due to inadequate clinical results emphasizes the necessity for robust data to support therapeutic viability. On a regulatory front, Strand Therapeutics stresses reforming the FDA's Investigational New Drug process to maintain U.S. leadership in biomedical innovation amid global competition. Passage Bio's strategic review following regulatory setbacks with its gene therapy program further exemplifies biotechnological unpredictability. Viridian Therapeutics' success with its anti-IGF-1R antibody bodes well for FDA approval and competition against established players like Amgen. The formation of the American Biotech Innovation Alliance signifies efforts to unify domestic biotech strategies amid global competition. Investments continue despite these challenSupport the show
Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Gene therapy approved to restore hereditary hearing loss; investigational treatment shows hair coverage improvements in male pattern loss; Breztri approved as a maintenance treatment for asthma; gene editing candidate meets endpoints in hereditary angioedema trial; novel dual glucagon/GLP-1 receptor agonist demonstrates significant weight loss.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to evolve rapidly with significant developments in drug approvals, regulatory changes, and innovative therapies. The latest updates highlight the tension between scientific advancement and regulatory scrutiny. A prime example is the FDA's proposal to rescind approval of Amgen's Tavneos due to alleged data manipulation and safety concerns. This action underscores the critical importance of rigorous data integrity and post-market surveillance in drug development. In a win for AstraZeneca, their Breztri Aerosphere has gained FDA approval for asthma treatment, strengthening its status as a blockbuster drug following its success in treating chronic obstructive pulmonary disease (COPD). This approval marks a significant milestone in AstraZeneca's ambition to achieve $80 billion in revenue by 2030. The inhaler's three-in-one formulation addresses a substantial unmet need in asthma management, offering enhanced convenience and efficacy for patients. Meanwhile, Novartis remains confident in its $5 billion peak sales projection for Pluvicto, even as it faces European regulatory setbacks and competitive pressures from bispecific antibodies. This scenario highlights the strategic resilience required by pharmaceutical companies to navigate regulatory landscapes and maintain market confidence amid challenges. Rocket Pharmaceuticals recently made headlines by selling a priority review voucher for $180 million following the approval of its gene therapy Kresladi. Such transactions are crucial for companies aiming to accelerate market entry for novel therapies, particularly in competitive fields like gene therapy. On the horizon for Kite Pharma, a subsidiary of Gilead Sciences, is the advancement of its next-generation CAR-T cell therapy for multiple myeloma. After refining its manufacturing processes, Kite is prepared to leverage its expertise in cell therapy to address the evolving landscape of hematologic malignancies. The potential approval of this therapy represents a significant step forward in personalized medicine and cancer treatment. GSK's ongoing legal dispute with AnaptysBio over Jemperli royalties emphasizes the complex interplay between strategic partnerships and intellectual property rights within the industry. As companies increasingly rely on collaborations for innovation, resolving such disputes amicably remains crucial for sustaining long-term alliances. Positive trial outcomes with Rezzayo from Mundipharma and CorMedix underscore an expanding focus on antifungal therapies, particularly for vulnerable populations like stem cell transplant recipients. This development could lead to broader prophylactic options against invasive fungal infections, improving patient outcomes in immunocompromised settings. Beyond therapeutic advancements, Medtronic's successful containment of a cyberattack highlights the growing importance of cybersecurity measures in safeguarding sensitive data and maintaining operational integrity. This incident reinforces the need for robust IT infrastructure within healthcare organizations to prevent disruptions and protect patient safety. Looking forward, Artificial Intelligence (AI) integration into pharma operations is reshaping traditional models from task execution to outcome ownership. AI-driven approaches are enabling life sciences organizations to scale impact, enhance decision-making processes, and accelerate value creation across drug discovery and development pipelines. Eli Lilly's collaboration with Profluent marks a significant move in the genetic medicine landscape. This $2.2 billion partnership focuses on developing AI-designed recombinases, a novel approach to gene editing that holds promise for addressing diseases with severe unmet needs. Recombinase-based Support the show
The suspect in the Correspondents' Dinner shooting appears in court, Britain's King Charles visits the United States, armed groups launch coordinated attacks across Mali, Iran strikes have reportedly caused billions of dollars in damage to U.S. bases, three people are killed in an alleged drug boat strike, 42 people are killed in clashes over a water dispute in Chad, China orders Meta to unwind its $2 billion Manus AI deal, the Trump administration fires all National Science Board members, and the FDA approves the first gene therapy for genetic deafness. Sources: Verity.News
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZP865. CME/AAPA/IPCE credit will be available until April 30, 2027.Driving Innovation Forward in Hemophilia B With Gene Therapy: Clinical Conversations on Progress and Guidance on Practical Delivery In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from CSL Behring.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZP865. CME/AAPA/IPCE credit will be available until April 30, 2027.Driving Innovation Forward in Hemophilia B With Gene Therapy: Clinical Conversations on Progress and Guidance on Practical Delivery In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from CSL Behring.Disclosure information is available at the beginning of the video presentation.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and regulatory updates that are shaping the future of the industry. At the latest meeting of the American Association for Cancer Research, innovative cancer therapies were in the spotlight. Merck showcased its PD-1xVEGF bispecific antibody for non-small cell lung cancer, combining immune checkpoint inhibition with anti-angiogenic strategies. This novel approach could enhance efficacy and safety compared to existing treatments. Despite these promising developments, Merck remains cautious about disclosing its Phase 3 trial plans, likely due to competitive pressures. The conference also featured industry veterans like Dr. Daniel Chen, who is pioneering "smart" cancer drugs through his startup. These antibody-drug conjugates aim to deliver targeted therapies with precision, minimizing off-target effects—a clear nod towards personalized medicine tailored to the genetic profiles of tumors. Revolution Medicines is making strides in targeting RAS mutations, particularly in pancreatic cancer, with its lead candidate daraxonrasib showing promise in Phase 3 trials. This positions the drug as a potential breakthrough for this challenging cancer type. Their broader pipeline suggests a strategic focus on exploiting RAS pathways, heralding a new wave of targeted cancer therapies. Meanwhile, National Cancer Institute Director Letai reassured attendees about stable research funding amidst political uncertainties, aiming to sustain momentum in cancer research advancements. Regulatory concerns were also a focal point at AACR. Dr. Richard Pazdur expressed anxiety over political influences impacting the U.S. FDA, reflecting broader challenges within regulatory frameworks that could affect drug approval processes and innovation timelines. On an international note, Zai Lab's global expansion ambitions were examined. Transitioning from licensing deals to independent biopharmaceutical development illustrates China's growing influence in biotech, though scaling operations across diverse regulatory environments presents significant challenges. In another significant development, Regeneron secured FDA approval for a pioneering gene therapy, underscoring rapid advances toward personalized therapies for genetic disorders. This marks a new era in genetic medicine and highlights the transformative potential of gene therapy. Meanwhile, Pfizer's strategic post-COVID-19 restructuring has resulted in further layoffs in Ireland, reflecting broader industry trends towards financial recalibration. Such moves underscore the ongoing adjustments companies face as they adapt to post-pandemic market dynamics. Pfizer's strategic portfolio management reflects a trend towards focusing resources on promising late-stage assets while deprioritizing earlier-stage projects that don't align with evolving goals. Roche's oral selective estrogen receptor degrader giredestrant remains a focal point despite clinical data concerns. Positioned as a potential major product in oncology, it illustrates the complexities involved in commercializing promising therapies amid data uncertainties. Sanofi continues to drive growth with Dupixent while preparing legal defenses to extend U.S. exclusivity beyond 2031—a strategic effort to protect revenue streams against generic competition. Conversely, AbbVie's attempt to introduce a Botox successor faced setbacks due to manufacturing-related issues flagged by the FDA, highlighting the complexities of meeting stringent regulatory standards. Avalyn Pharma's $182 million IPO signifies strong investor confidence in late-stage respiratory drug candidates, emphasizing efforts to innovate in chronic disease management. Regulatory dynamics are evolving too, with initiatives aimed at exSupport the show
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZP865. CME/AAPA/IPCE credit will be available until April 30, 2027.Driving Innovation Forward in Hemophilia B With Gene Therapy: Clinical Conversations on Progress and Guidance on Practical Delivery In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from CSL Behring.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZP865. CME/AAPA/IPCE credit will be available until April 30, 2027.Driving Innovation Forward in Hemophilia B With Gene Therapy: Clinical Conversations on Progress and Guidance on Practical Delivery In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from CSL Behring.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZP865. CME/AAPA/IPCE credit will be available until April 30, 2027.Driving Innovation Forward in Hemophilia B With Gene Therapy: Clinical Conversations on Progress and Guidance on Practical Delivery In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from CSL Behring.Disclosure information is available at the beginning of the video presentation.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Regeneron has recently achieved a pivotal milestone with the FDA's approval of its hearing loss gene therapy, Otarmeni. This approval, facilitated through the FDA's Commissioner's National Priority Voucher Program, emphasizes the expanding recognition of gene therapies as essential therapeutic modalities. Otarmeni stands out as it directly targets an underlying genetic cause of hearing loss, marking a significant advancement in audiological medicine. Traditionally, hearing loss has been managed with hearing aids or cochlear implants, which do not address the root cause. Otarmeni represents a transformative approach by correcting genetic deficiencies, offering patients a chance for improved auditory function. This achievement not only highlights Regeneron's innovative capabilities but also sets a precedent encouraging other companies to explore genetic disorder treatments. Eli Lilly's development of AK-OTOF, targeting otoferlin deficiencies crucial for auditory processes, further signifies robust competition in this space. Currently under Phase 1/2 clinical trials, AK-OTOF is anticipated to continue research efforts until 2028. These advancements illustrate a promising pipeline of treatments that could potentially revolutionize patient care. The regulatory landscape is adapting to accommodate such novel therapies, with programs like the FDA's National Priority Voucher Program playing a crucial role in expediting access to groundbreaking treatments. From a scientific perspective, therapies like Otarmeni underscore the importance of understanding genetic mechanisms in disease pathogenesis. By modifying faulty genes within cells, these therapies offer hope not only for hearing loss but for a range of genetic disorders as well. Turning our attention to Novo Nordisk's progress with oral semaglutide for adolescent Type 2 diabetes; the company has announced positive clinical trial results extending its use beyond obesity treatment. This development is significant given the increasing prevalence of Type 2 diabetes among younger populations. Oral GLP-1 receptor agonists could revolutionize diabetes management by providing an alternative to injections, potentially improving compliance and quality of life for patients. In regulatory practices, there is a growing call for transparency. A citizen petition urges the FDA to refine disclosure protocols concerning Complete Response Letters (CRLs), aligning with industry demands for clarity in drug approval processes. Enhanced transparency could lead to more efficient regulatory pathways and strengthen trust between pharmaceutical companies and regulators. Roche's recent earnings report reveals challenges beyond currency fluctuations, as several key drugs underperformed against expectations. This raises questions about Roche's strategic positioning amid intense competition and market dynamics. Conversely, AbbVie's $1.4 billion investment in North Carolina to establish a new production base highlights strategic expansions aimed at meeting rising pharmaceutical demand. Technological innovation continues shaping industry strategies with Merck & Co.'s collaboration with Google Cloud aimed at enhancing AI capabilities—a $1 billion initiative focusing on transforming healthcare professional engagement through data analytics and AI insights. Such collaborations are likely to optimize marketing strategies and improve patient outcomes by facilitating personalized healthcare interactions. Meanwhile, Sanofi's defense of Dupixent amid R&D setbacks exemplifies how breakthrough biologics can drive revenue growth despite challenges. These developments highlight an industry undergoing transformation towards transparency, innovative treatments, strategic expansion, and technological adoption—promisingSupport the show
Nicole Johnson and Nasha Fitter are both mothers of daughters with the ultra-rare neurodevelopmental condition FOXG1 syndrome, which currently has no approved disease-modifying therapies. The disorder causes profound developmental disabilities, epilepsy, motor and speech impairments, and multi-system challenges. The two mothers co-founded the FOXG1 Research Foundation to advance treatments for the condtion. Johnson and Fitter discuss how a parent-driven foundation became a virtual biotech capable of advancing a gene therapy into human clinical trials, how they prioritized translational work over academic projects that don't move a therapy toward the clinic, and the lessons they've learned that can guide other rare disease communities.
Dr. Gabriel Brooks is Chief Medical Officer at Solid Biosciences, a precision molecular genetic medicines company focused on rare cardiovascular and neuromuscular diseases, including Friedreich's ataxia. Currently, there are very limited treatments for this rare, progressive neurologic disease caused by a genetic deficiency. Solid Biosciences' novel gene therapy uses dual-route administration to deliver directly to the heart and brain and to replace the missing frataxin gene, which is critical for energy production. Dr. Brooks explains, "Our flagship program is our DMD program, where we have two clinical trials, a first-in-human INSPIRE study, and a double-blind randomized placebo-controlled phase three trial for the SGT-003 DMD medicine. And for Friedreich's ataxia, we have the SGT-212 program, which uses a novel dual route of administration to target not only the cardiomyopathy, but also uses direct injection into the dentate nucleus. We're trying to address the central pathophysiology of the ataxia that patients live with every day." "So Friedrich's ataxia is a rare and devastating neurologic disease that afflicts around 5,000 patients in the United States and much more actually in Europe. There is a genetic predisposition. And Friedrich's ataxia is really a disease where the patients experience difficulty in moving, what's called ataxia, which you could think of as poor coordination, where when they try to move, their brain is sending a signal to their muscles, let's say to grab that cup of coffee or climb the stairs." "In fact, there are specific neurologic tests in terms of looking at nerve conduction and other things that can make the formal diagnosis. And certainly, we can get there with genetic testing. And what you're picking up on is absolutely something that's important with rare disease, is that oftentimes there's a lag between when a patient first manifests symptoms and when they ultimately have the diagnosis. In Friedrich's ataxia, like other genetic diseases, it is horrible. And so, for patients who do make the diagnosis of Friedreich's ataxia, there is often what we call cascade screening, where we look for the disease gene in relatives. Oftentimes, it's then that siblings are identified, and eventually they start manifesting the disease as well." #SolidBiosciences #GeneTherapy #GeneTherapyResearch #RareDiseases #FriedreichsAtaxia #PrecisionMedicine #Neurology #Cardiology #ClinicalTrials #MedicalInnovation #HealthcareInnovation #SolidBiosciences solidbio.com Download the transcript here
Dr. Gabriel Brooks is Chief Medical Officer at Solid Biosciences, a precision molecular genetic medicines company focused on rare cardiovascular and neuromuscular diseases, including Friedreich's ataxia. Currently, there are very limited treatments for this rare, progressive neurologic disease caused by a genetic deficiency. Solid Biosciences' novel gene therapy uses dual-route administration to deliver directly to the heart and brain and to replace the missing frataxin gene, which is critical for energy production. Dr. Brooks explains, "Our flagship program is our DMD program, where we have two clinical trials, a first-in-human INSPIRE study, and a double-blind randomized placebo-controlled phase three trial for the SGT-003 DMD medicine. And for Friedreich's ataxia, we have the SGT-212 program, which uses a novel dual route of administration to target not only the cardiomyopathy, but also uses direct injection into the dentate nucleus. We're trying to address the central pathophysiology of the ataxia that patients live with every day." "So Friedrich's ataxia is a rare and devastating neurologic disease that afflicts around 5,000 patients in the United States and much more actually in Europe. There is a genetic predisposition. And Friedrich's ataxia is really a disease where the patients experience difficulty in moving, what's called ataxia, which you could think of as poor coordination, where when they try to move, their brain is sending a signal to their muscles, let's say to grab that cup of coffee or climb the stairs." "In fact, there are specific neurologic tests in terms of looking at nerve conduction and other things that can make the formal diagnosis. And certainly, we can get there with genetic testing. And what you're picking up on is absolutely something that's important with rare disease, is that oftentimes there's a lag between when a patient first manifests symptoms and when they ultimately have the diagnosis. In Friedrich's ataxia, like other genetic diseases, it is horrible. And so, for patients who do make the diagnosis of Friedreich's ataxia, there is often what we call cascade screening, where we look for the disease gene in relatives. Oftentimes, it's then that siblings are identified, and eventually they start manifesting the disease as well." #SolidBiosciences #GeneTherapy #GeneTherapyResearch #RareDiseases #FriedreichsAtaxia #PrecisionMedicine #Neurology #Cardiology #ClinicalTrials #MedicalInnovation #HealthcareInnovation #SolidBiosciences solidbio.com Listen to the podcast here
There are few neurodegenerative diseases as devastating as Huntington's. It's sometimes likened to having Parkinson's, ALS and Alzheimer's all at the same time, with symptoms that include progressive motor dysfunction, cognitive decline and behavioural change. It's also hereditary — if a person has the faulty gene that causes the disease, there's a 50 percent chance their children will have it, too. In the fall of 2025, however, scientists announced that, for the first time, they could reduce the progression of Huntington symptoms using a new gene therapy. While that clinical breakthrough came with several caveats, it also heralded a possible new paradigm for drug discovery. In this episode, we explore how this innovative therapy works and what it could mean for the treatment of other rare diseases. Featured in this episode: Rachel Harding is an assistant professor in the department of pharmacology and toxicology at the University of Toronto and a principal investigator at the Structural Genomics Consortium. Her work on Huntington's disease has been recognized with major early-career awards, highlighting both scientific excellence and the potential patient impact of her research program. Further reading: Research is unravelling the mystery of what causes Huntington's disease, a devastating brain disease In a first, a gene therapy seems to slow Huntington disease “Best news” for Huntington's disease community comes with unanswered questions The Huntington's disease research pipeline World's first patient treated with personalized CRISPR gene editing therapy at Children's Hospital of Philadelphia Solve for X is brought to you by MaRS, North America's largest urban innovation hub and a registered charity. MaRS supports startups and accelerates the adoption of high-impact solutions to some of the world's biggest challenges. For more information, visit marsdd.com.
In this episode, we discuss the 3 year results of the Phase 2 trial of the Adverum intravitreal gene therapy with Dr. Dilsher Dhoot, California Retina Consultants, Adjunct Clinical Professor Ophthalmology, Keck School of Medicine of USC.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore some of the pivotal shifts and breakthroughs shaping the industry and their implications for drug development and patient care. In oncology, Merck & Co.'s Welireg triplet therapy faced a setback in its Phase 3 trial for first-line treatment of kidney cancer. Despite previous successes, this outcome underscores the complexity of developing oncology treatments and illustrates the ongoing need for innovative approaches to meet diverse patient needs. Meanwhile, Roche has reported promising results for Enspryng in its Phase 3 trial, demonstrating a 68% reduction in relapse risk for a rare neuroinflammatory disorder. This success highlights Roche's commitment to addressing unmet needs in rare diseases and paves the way for potential FDA approval. AstraZeneca continues to advance with Ultomiris, which showed significant results in reducing protein levels in urine for IgA nephropathy patients. This success not only expands Ultomiris' indications but also underscores AstraZeneca's focus on rare diseases, positioning them as leaders in this specialized market. Additionally, AstraZeneca's Tozorakimab met primary endpoints in COPD trials, showcasing new possibilities for managing this prevalent respiratory disease. On another front, Zai Lab's strategic evolution from licensing major pharma drugs to developing its own pipeline marks a significant maturation of China's biotech capabilities. This reflects a broader trend of Chinese firms seeking global footprints while navigating regulatory challenges to gain international credibility. Regulatory and strategic news also has its highlights: Pfizer is undergoing changes as its Chief Strategy and Innovation Officer steps down, possibly signaling a shift in strategic direction. Replimune's drastic workforce reduction following an FDA rejection exemplifies the harsh realities biotech companies face in regulatory pathways. Meanwhile, Gilead's retraction from a collaboration with Arcus Biosciences after a Phase 3 failure underscores the risks associated with antibody-based therapies. In other collaborations, Roche's Foundation Medicine is deepening ties with Bristol Myers Squibb to develop new diagnostic targets, illustrating how partnerships can drive innovation by leveraging combined expertise. In industry trends, there's a growing integration of medical affairs with commercial operations to optimize scientific exchange and product launches—this alignment is critical for ensuring new therapies reach patients efficiently. Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion signals an increased focus on in vivo CAR-T capabilities. This acquisition could streamline cancer treatments by engineering T-cells directly within patients' bodies, offering potentially more effective therapeutic approaches. Globally, Biogen has expanded its partnership with TJ Biopharma for Felzartamab rights in China, reflecting strategic moves to penetrate Asian markets. GSK's Blenrep received Chinese approval for treating multiple myeloma, marking a significant advancement with this antibody-drug conjugate targeting BCMA. In Canada, ClearPoint Neuro gained approval for its neuro navigation system, highlighting precision medicine's role in enhancing therapeutic outcomes. The technological landscape is also evolving with Serif pioneering DNA-based therapeutics. Supported by Flagship Pioneering's $50 million investment, these innovations could revolutionize personalized medicine by offering tailored solutions. Ray Therapeutics' $125 million funding advancement in gene therapy candidates targeting retinal degeneration further underscores interest in genetic therapies as viable treatment options. In regulatory landscapes, there's a push for designing neurodegenerative trials that Support the show
Al's back with a tight commute sprint: London rolls out the red carpet for the BAFTA Games Awards, as Clair Obscur: Expedition 33 nabs Best Game and Dispatch hoovers up the craft gongs. Then Tesco quietly tries to bin the barcode — swapping in QR codes on sausage packs, because even your weekly shop is basically software now. We've also got a proper science win as Luxturna's sight-restoring gene therapy team bags a Breakthrough Prize, plus a geology breakthrough that could help locate the rare earth minerals powering everything from phones to clean tech. Read more at standard.co.uk — and follow Tech and Science Daily from The Standard for your weekday briefing. Hosted on Acast. See acast.com/privacy for more information.
What is ocular gene therapy, and could it treat inherited retinal diseases like Stargardt and Usher syndrome? In this episode, I'm joined by Dr. Jayashree Sahni of AAVantgarde to break down how gene therapy works, what clinical trials involve, and what patients can expect. We cut through the myths and explore the real potential of gene therapy for vision loss. Contact AAVantgarde to learn more: ► www.aavantgarde.com ► clinicaltrials@aavantgarde.com ► patientadvocacy@aavantgarde.com Get the full transcription here: ► https://docs.google.com/document/d/17yR24WkAZ2lHd1iCoKXtANoZ-vFd6XqU5K5d154kjgE/edit?usp=sharing #GeneTherapy #Stargardts #RetinitisPigmentosa #Blindness #VisionLoss #AssistiveTechnology #ClinicalTrials #EyeHealth #AAVantgarde
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. This week, we delve into a series of compelling stories that are shaping the future of drug development, therapeutic innovation, and patient care. The gene therapy sector is currently under the spotlight, with Johnson & Johnson handing back the rights to botaretigene sparoparvovec to MeiraGTx following a phase 3 trial failure. This underscores the inherent challenges in developing treatments for rare diseases, where the stakes are high and financial consequences significant. Despite this setback, optimism persists in the industry. Ocugen, for instance, is forging ahead with plans for multiple gene therapy approvals in the coming years. Their strategy focuses on broadening access to these treatments, reflecting a shift towards achieving commercial scalability alongside technical innovation. The funding landscape for biotech startups is experiencing a downturn, with early-stage financing at its lowest post-pandemic levels. This poses substantial challenges to innovation-driven companies that rely on robust funding environments to propel their research forward. However, not all news is bleak; strategic partnerships are proving to be a valuable avenue for growth. Aligos Therapeutics' collaboration with Amoytop in China exemplifies how geographic strategies can unlock value and optimize resources across regions. In Alzheimer's research, anti-amyloid drugs are under renewed scrutiny. Despite FDA approvals, their efficacy has come into question, shedding light on the complexities of translating mechanistic hypotheses into clinical success. This ongoing debate highlights the necessity for innovative approaches that offer more definitive clinical benefits. On the regulatory front, significant changes are underway as seen with the FDA's reclassification of peptides ahead of an advisory committee meeting. This move indicates a commitment to maintaining rigorous safety and efficacy standards amid evolving scientific practices. Meanwhile, Eli Lilly's proactive measures in addressing FDA safety concerns for its obesity drug Foundayo demonstrate how companies are navigating regulatory landscapes to expand therapeutic indications while ensuring compliance. Adaptive trial designs are making headway in oncology, offering a promising method to accelerate cancer drug approvals through real-time data analysis. These flexible methodologies signify a shift towards more dynamic regulatory approaches that can expedite patient access to novel therapies. Spain's initiative to integrate its biotech sector with Boston's life sciences ecosystem through a $200 million venture capital fund represents a strategic push towards fostering innovation and growth. This cross-continental collaboration aims to leverage Boston's advanced infrastructure and expertise, enhancing Spanish biotechs' global competitiveness. In business news, Beeline Medicines' impressive $300 million Series A funding highlights a trend towards substantial investments in emerging biotech firms with promising drug candidates. By licensing compounds from Bristol Myers Squibb, Beeline is poised to make significant strides in autoimmune therapeutics. Sandoz's agreement with Rwanda marks an important step towards addressing healthcare needs in Africa by providing essential medicines for infectious diseases and oncology. This partnership underscores the growing importance of global collaborations in enhancing healthcare accessibility. The acquisition of QIMR Berghofer's epigenetic drug discovery platform by Kazia Therapeutics reflects the increasing interest in leveraging AI/ML-driven approaches within oncology and drug discovery sectors. Such strategic expansions are emblematic of broader industry trends towards precision medicine. In an era where technological innovations redefine Support the show
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a fascinating realm where technology and biology converge, starting with a deepening relationship between biopharma and artificial intelligence. Novartis CEO Vas Narasimhan's recent appointment to the board of AI company Anthropic signals the strategic integration of AI into drug discovery and development processes. This collaboration highlights a growing trend where pharmaceutical companies are increasingly leveraging AI to optimize clinical trials, streamline drug discovery, and personalize patient care strategies. Similarly, Novo Nordisk has announced a strategic partnership with OpenAI to integrate AI technologies across various facets of its operations, including drug discovery and manufacturing. By leveraging OpenAI's machine learning capabilities, Novo Nordisk aims to streamline research efforts and accelerate therapeutic identification—a collaboration reflecting AI's growing role as an essential tool for maintaining competitiveness in drug development. Additionally, Amazon Web Services' launch of the Amazon Bio Discovery AI tool marks another milestone. Designed to expedite antibody design and drug discovery processes, it provides researchers with robust AI-driven platforms enhancing therapeutic design speed and accuracy. The emphasis on monoclonal antibodies aligns with industry trends focusing on targeted therapies for diseases such as cancer. Meanwhile, Eli Lilly's new obesity treatment, Foundayo, has caught the FDA's attention due to potential safety concerns. Despite progressing with its launch, the FDA has requested additional safety information to address unexpected serious risks associated with the drug. This highlights the ongoing regulatory scrutiny that accompanies novel treatments, especially in areas like obesity where patient populations are large and diverse. In another strategic move, Eli Lilly's acquisition of Crossbridge Bio for up to $300 million aims to bolster its oncology pipeline with dual-payload antibody-drug conjugates (ADCs). This acquisition reflects a strategic move enhancing Eli Lilly's position in oncology by integrating cutting-edge ADC technologies known for delivering cytotoxic agents directly to cancer cells while minimizing off-target effects. On another front, Travere Therapeutics is mapping a pathway to a potential $3 billion opportunity in the U.S. market following significant approval for its treatment Filspari, targeted at rare kidney diseases. This approval underscores the increasing focus on rare diseases, which present lucrative opportunities for pharmaceutical companies due to significant unmet needs and often high-cost treatments. Astellas' manufacturing strategy underscores the importance of reliable supply as a critical bridge from research to patient care. Led by Chief Manufacturing Officer Rao Mantri, this strategy highlights how manufacturing excellence can significantly impact drug availability and patient outcomes. It emphasizes that production reliability is vital in ensuring groundbreaking research translates into accessible medical treatments. In contrast, a slowdown in IPOs has been noted amidst an aggressive merger and acquisition spree by major pharmaceutical companies. This consolidation trend reflects strategic shifts within the industry as companies seek to bolster pipelines through acquisitions rather than organic growth. Such dynamics indicate a strategic pivot as firms prioritize acquiring promising assets over developing them from scratch. Ionis Pharmaceuticals' recent win in a drug naming competition exemplifies the complexities involved in branding within the pharmaceutical sector. Crafting a drug name that is memorable yet distinctive involves balancing marketability with regulatory requirements—a reflection of the intSupport the show
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
A clinical pharmacy leader outlines 8 interdependent domains institutions must master to build financially sustainable, patient-accessible CGT programs.
CSL Behring just announced a global "stockout" of Hemgenix—what's happening, and what does it mean for patients? On this episode of BloodStream Podcast, we break down the news, launch our mini-series on plasma donation, and hear from Thomas Savage in our I'm Fine segment, sharing the highs, the lows, and the reality of living with a severe bleeding disorder. Pain, perseverance, and the lessons learned along the way give a rare, unfiltered glimpse into life behind the headlines—reminding us all that every treatment, every donation, and every day matters. Show Notes: I'm Fine is presented by @SanofiUS #bloodstreammedia #raredisease #bleedingdisorders #podcast #chronicdisease #hemophiliacommunity #advocacy Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more. Subscribe: The BloodStream Podcast Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook BloodStream on X/Twitter BloodStream on Instagram BloodStream on LinkedIn BloodStream on TikTok
Strategic funding extends cash runway through 2029 and advances multiple inherited retinal disease programs
It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Senate Insulin Act moves forward, FDA approveds Awiqli for type 2 and and second oral GLP-1 pill, lots of updates on stem cell and gene therapy for type 1, updates from Beta Bionics, veterans group and Dexcom team up, and Omnipod features on Scrubs. Much more in the episode! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Stacey mentioned these two groups: Grownup T1Ds T1D to 100 Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com
In this episode of Sounds of Science, Lauren and Matt Noonan share their powerful journey following their daughter Jane's diagnosis with Mowat-Wilson Syndrome. From unexpected medical challenges to finding community and launching their own nonprofit, the OURS Foundation, they discuss how advocacy, collaboration, and emerging research are shaping new hope for families living with rare diseases. Charles River | ASO Development Charles River | ASO Screening Services Charles River | Rare Disease Charles River | Rare Disease Research for Drug Development Mowat Wilson Foundation
Emily Walsh Martin, PhD, spoke with Amber Freed, founder and CEO of SLC6A1 Connect, a patient organization focused on accelerating the development of therapies for SLC6A1 patients like her son Maxwell.Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.
In this episode, Adam Torres interviews Dr. Alex Levin, Chief of Pediatric Ophthalmology and Ocular Genetics at the Flaum Eye Institute, University of Rochester. Dr. Levin shares how his team is developing low-cost, open-access gene therapies to treat and prevent blindness worldwide. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices
Health-system pharmacies must take an active role in onboarding these therapies including evaluating biosafety precautions along the medication use pathway, assisting with the development of infrastructure to administer and monitor these therapies, and identifying the practical and financial implications of these therapies within the health-system. This episode will review organizational considerations and strategies around these novel therapies including complexities and structures of supply chain operations, financial models and impacts, clinical operations needs and planning, and interdisciplinary alignment and collaboration. CE for this episode expires 3 years after the date it was originally published. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
© 2020-2026 Ivy Podcast Discovery LLC
